Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7669330 in Geographic Atrophy Secondary to AMD
NCT06961370Phase 1Terminated
- Sponsor
- Roche
- Start
- Jul 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RO7669330 in geographic atrophy (GA) and age-related macular degeneration (AMD) (3 arms), sponsored by Roche. Primary endpoints: Number of Participants With Adverse Events at 34 weeks and Number of Participants With Abnormalities Recorded in Standard Ophthalmological Assessments at 34 weeks. Started Jul 2025; status: terminated.
02
Drugs
RO7669330
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT06961370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961370.